Santhera Appoints Stifel as Corporate Finance Advisor

On February 10, 2026, Santhera Pharmaceuticals, a Swiss company listed on the SIX Swiss Exchange under the ticker SANN, announced its strategic appointment of Stifel Nicolaus Europe Limited as a corporate finance advisor. This partnership aims to enhance the company’s capital markets initiatives and broaden its outreach to international institutional investors. Stifel will work in conjunction with Octavian AG, which has been maintaining an advisory role, to expand the company's investor engagement and market presence, particularly in the context of financing and strategic growth.

Santhera Pharmaceuticals specializes in developing and commercializing innovative treatments for rare neuromuscular diseases, addressing significant unmet medical needs. Notably, the company holds an exclusive global license for AGAMREE® (vamorolone), a unique dissociative steroid designed as an alternative treatment for Duchenne muscular dystrophy (DMD), a severe genetic disorder affecting muscle degeneration. AGAMREE has received regulatory approval from multiple health authorities, including the FDA in the U.S. and the European Commission, signifying its viability and the potential impact on patients with DMD.

In addition to its direct offerings, Santhera has established partnerships for AGAMREE’s distribution in various regions: Catalyst Pharmaceuticals manages its North America rights, while Sperogenix Therapeutics and Nxera Pharma handle distribution in China and specified Asia-Pacific markets, respectively.

The collaboration with Stifel is expected to reinforce Santhera’s growth trajectory, as the company seeks to attract wider investor interest while continuing its commitment to developing essential therapeutic solutions for underserved patient populations.

Santhera Pharmaceuticals’ recent appointment of Stifel Nicolaus as a corporate finance advisor, alongside ongoing collaboration with Octavian AG, signals a strategic move aimed at enhancing capital market presence and engaging international institutional investors. This development comes at a pivotal time for Santhera, especially with its flagship product, AGAMREE® (vamorolone), gaining traction in multiple regulated markets.

Investors should view this dual advisory relationship positively, as it may facilitate improved access to funding, strategic partnerships, and enhanced visibility within the global capital markets. Stifel’s established network can be instrumental in connecting Santhera with larger institutional investors, potentially driving stock liquidity and investor confidence.

Santhera's focus on innovative treatments for rare neuromuscular diseases positions it uniquely within the biopharmaceutical sector, particularly as AGAMREE® addresses high unmet medical needs in patient populations, such as those suffering from Duchenne muscular dystrophy (DMD). The recent regulatory approvals from major markets, including the U.S., EU, and Canada, underline the product's viability and its commercial potential.

However, while optimism is warranted, investors should maintain a cautious outlook due to inherent market risks, including potential delays in further approvals and the competitive landscape within the rare disease sector. Furthermore, international collaborations, as seen with the out-licensing of AGAMREE® to various partners, will be crucial in expanding market reach and revenues.

In summary, Santhera's strategic initiatives to enhance its capital market footprint through Stifel and Octavian, combined with its promising pipeline, presents an attractive opportunity for investors. Nevertheless, careful evaluation of market conditions and company performance will be essential in navigating potential risks inherent in the biopharmaceutical industry.